Lianyungang Enterprises Listed on Global Top 50 Pharmaceutical Enterprises Again

From: Lianyungang Updated: 2021-06-16 10:54

On June 11, PharmExec published the list of Global Top 50 Pharmaceutical Enterprises in 2021. This year, five Chinese pharmaceutical companies were listed, and the number was an all-time record. Among them, Hengrui Medicine entered the list for three consecutive years, and the ranking rose year by year from 47th in 2019 to 38th. It is worth mentioning that in the R&D investment of pharmaceutical enterprises in the list, Hengrui Medicine ranked 34th with $714 million, ranking first in the list of Chinese pharmaceutical enterprises. The relevant person in charge of the Municipal Science and Technology Bureau said that through innovation, Lianyungang enterprises are gradually entering the forefront of global pharmaceutical research and development and showing a strong innovative power.

It is known that PharmExec's list of the Global Top 50 Pharmaceutical Enterprises has been published once a year since 2000 and has been published for 22 consecutive times. The ranking of the list is mainly based on the global sales revenue of preion drugs of each enterprise in 2020, so it is considered as the list reflecting the overall strength of medical business of each company. According to the relevant person in charge of the Lianyungang Municipal Bureau of Industry and Information Technology, two of the five Chinese enterprises that entered the list have close relations with Lianyungang. Hengrui Medicine is the most important pharmaceutical enterprise in Lianyungang with many core products. Chiatai Tianqing, another pharmaceutical company in Lianyungang, is one of the core biopharmaceutical companies in China. In 2020, three Chinese biopharmaceutical products exceeded $100 million, of which Runzhong, the largest one, is supplied by Chiatai Tianqing.

Hengrui Medicine being among the global list is attributable to the sales volume of its heavyweight innovative product Etam (namely apatinib mesylate tablets) in 2020. According to the Top 50 List, its sales volume was $392 million. Its second largest contributor was generic docetaxel, with annual sales of $208 million. Pyrrolotinib, an innovative drug, has been paid attention to in this list for the first time and become a hot product of Hengrui in 2020 with a sales performance of $198 million. Among the three heavyweight products of China's biopharmaceutical industry, Runzhong, the largest one, comes from Chiatai Tianqing, a Lianyungang company, with annual sales of $506 million.

According to the staff in charge of the Municipal Bureau of Science and Technology, at present, Lianyungang pharmaceutical industry has established an enterprise-oriented, market-oriented, joint development R&D system of industry, university and research. The universities it cooperates with consist of domestic well-known pharmaceutical R&D institutions and universities. They also cooperate with Harvard University, MD Anderson Cancer Center of University of Texas, MD Anderson Cancer Center of University of Texas Mayo Clinic and other world-famous R&D institutions to establish good cooperative relations and set up R&D centers in Shanghai, Nanjing, Chengdu and other cities, as well as in the United States, Japan and other countries. There are more than 6000 R&D personnel in the industry, including more than 4000 with master’s degree and more than 100 foreign employees. At the same time, Lianyungang pharmaceutical industry has also built a research and development system in line with international standards. The proportion of R&D investment of leading enterprises in sales has been maintained at more than 8% for a long time, and a series of platform carriers such as state key laboratory, national engineering center and industrial research institute have been built. All these guarantee that "Lianyungang pharmaceutical industry will offer new drugs every year, and innovative drugs will be approved to enter the market every two to three years".